Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient

AIDS. 2011 Nov 28;25(18):2306-8. doi: 10.1097/QAD.0b013e32834cdb89.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Anti-HIV Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Drug Therapy, Combination
  • Emtricitabine
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Protease Inhibitors / therapeutic use
  • HIV-2 / immunology
  • Humans
  • Lopinavir / therapeutic use
  • Male
  • Middle Aged
  • Organophosphonates / therapeutic use
  • Pyrrolidinones / administration & dosage
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Ritonavir / therapeutic use
  • Salvage Therapy / methods*
  • Tenofovir
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • HIV Protease Inhibitors
  • Organophosphonates
  • Pyrrolidinones
  • Deoxycytidine
  • Lopinavir
  • Raltegravir Potassium
  • Tenofovir
  • Emtricitabine
  • Adenine
  • Ritonavir